Mediclinic International (LON:MDC) Given “Hold” Rating at Berenberg Bank

Mediclinic International (LON:MDCGet Rating)‘s stock had its “hold” rating reaffirmed by investment analysts at Berenberg Bank in a research note issued to investors on Tuesday, Digital Look reports. They currently have a GBX 464 ($5.68) price objective on the stock. Berenberg Bank’s price target would suggest a potential upside of 3.90% from the company’s previous close.

Separately, Barclays lifted their price objective on shares of Mediclinic International from GBX 385 ($4.72) to GBX 460 ($5.63) and gave the company an “overweight” rating in a report on Tuesday, May 31st.

Shares of MDC stock opened at GBX 446.60 ($5.47) on Tuesday. The company has a debt-to-equity ratio of 79.76, a quick ratio of 1.67 and a current ratio of 1.79. The stock has a market capitalization of £3.29 billion and a P/E ratio of 21.66. The company has a 50 day moving average price of GBX 385.68 and a 200 day moving average price of GBX 349.05. Mediclinic International has a fifty-two week low of GBX 271.40 ($3.32) and a fifty-two week high of GBX 458.20 ($5.61).

In other news, insider Tom Singer purchased 20,000 shares of the stock in a transaction on Wednesday, May 25th. The stock was bought at an average price of GBX 366 ($4.48) per share, for a total transaction of £73,200 ($89,661.93).

Mediclinic International Company Profile (Get Rating)

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 74 hospitals, 18 day case clinics, 18 outpatient clinics, 5 subacute hospitals, 2 mental health facilities, and 454 theatres with approximately 11,?449 inpatient beds in Switzerland, South Africa, Namibia, and the United Arab Emirates.

Further Reading

Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.